Modeling of Fabry disease nephropathy using patient derived human induced pluripotent stem cells and kidney organoid system

[1]  B. Humphreys,et al.  Determining epigenetic memory in kidney proximal tubule cell derived induced pluripotent stem cells using a quadruple transgenic reprogrammable mouse , 2022, Scientific Reports.

[2]  K. Schlingmann,et al.  The genetic spectrum of Gitelman(-like) syndromes , 2022, Current opinion in nephrology and hypertension.

[3]  S. Borwornpinyo,et al.  Establishment and Characterization of MUi027-A: A Novel Patient-Derived Cell Line of Polycystic Kidney Disease with PKD1 Mutation , 2022, Journal of personalized medicine.

[4]  E. Svarstad,et al.  Reduced α-galactosidase A activity in zebrafish (Danio rerio) mirrors distinct features of Fabry nephropathy phenotype , 2022, Molecular genetics and metabolism reports.

[5]  C. Cheon,et al.  Fabry nephropathy before and after enzyme replacement therapy: important role of renal biopsy in patients with Fabry disease , 2021, Kidney research and clinical practice.

[6]  N. Carrera,et al.  Molecular Basis, Diagnostic Challenges and Therapeutic Approaches of Bartter and Gitelman Syndromes: A Primer for Clinicians , 2021, International journal of molecular sciences.

[7]  B. Chung,et al.  Modeling of endothelial cell dysfunction using human induced pluripotent stem cells derived from patients with end-stage renal disease. , 2021, Kidney research and clinical practice.

[8]  S. Nam,et al.  Human kidney organoids reveal the role of glutathione in Fabry disease , 2021, Experimental & Molecular Medicine.

[9]  Ho-Shik Kim,et al.  Fabry disease exacerbates renal interstitial fibrosis after unilateral ureteral obstruction via impaired autophagy and enhanced apoptosis , 2021, Kidney research and clinical practice.

[10]  E. Riccio,et al.  DNA methylation impact on Fabry disease , 2021, Clinical epigenetics.

[11]  B. Chung,et al.  Human-induced pluripotent stem cell lines (CMCi006-A and CMCi007-A) from a female and male patient with Fabry disease carrying the same frameshift deletion mutation. , 2021, Stem cell research.

[12]  B. Chung,et al.  Generation of a human induced pluripotent stem cell line (CMCi002-A) from a patient with Gitelman's syndrome. , 2020, Stem cell research.

[13]  J. Oliveira,et al.  Accumulation of Globotriaosylceramide in Podocytes in Fabry Nephropathy Is Associated with Progressive Podocyte Loss. , 2020, Journal of the American Society of Nephrology : JASN.

[14]  F. Endo,et al.  Newborn screening for Fabry disease in the western region of Japan , 2020, Molecular genetics and metabolism reports.

[15]  Sang-Hyun Min,et al.  Generation of a GLA knock-out human-induced pluripotent stem cell line, KSBCi002-A-1, using CRISPR/Cas9. , 2019, Stem cell research.

[16]  Benjamin S. Freedman,et al.  Profiling APOL1 Nephropathy Risk Variants in Genome-Edited Kidney Organoids with Single-Cell Transcriptomics , 2019, bioRxiv.

[17]  Su Nam Lee,et al.  A Case of a 50-Year-Old Woman with Typical Fabry Disease Who Showed Serial Electrocardiographic and Echocardiographic Changes over a 17-Year Period , 2019, Case reports in cardiology.

[18]  J. Shayman,et al.  α-galactosidase A deficiency promotes von Willebrand factor secretion in models of Fabry disease. , 2019, Kidney international.

[19]  R. Nishinakamura,et al.  Organoids from Nephrotic Disease-Derived iPSCs Identify Impaired NEPHRIN Localization and Slit Diaphragm Formation in Kidney Podocytes , 2018, Stem cell reports.

[20]  H. Tojo,et al.  Generation of Fabry cardiomyopathy model for drug screening using induced pluripotent stem cell-derived cardiomyocytes from a female Fabry patient. , 2018, Journal of molecular and cellular cardiology.

[21]  Benjamin S. Freedman,et al.  CRISPR Gene Editing in the Kidney. , 2018, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[22]  S. Ortolano,et al.  Fabry disease in the Spanish population: observational study with detection of 77 patients , 2018, Orphanet Journal of Rare Diseases.

[23]  Benjamin S. Freedman,et al.  Organoid cystogenesis reveals a critical role of microenvironment in human polycystic kidney disease , 2017, Nature materials.

[24]  Yeri Alice Rim,et al.  Induced Pluripotent Stem Cell Generation from Blood Cells Using Sendai Virus and Centrifugation. , 2016, Journal of visualized experiments : JoVE.

[25]  Ho-Shik Kim,et al.  Identification of a novel GLA mutation (Y88C) in a Korean family with Fabry nephropathy: a case report , 2016, BMC Medical Genetics.

[26]  Manesh R. Patel,et al.  Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry , 2016, Journal of Medical Genetics.

[27]  E. Riccio,et al.  Molecular and clinical studies in five index cases with novel mutations in the GLA gene. , 2016, Gene.

[28]  K. Xia,et al.  GLA variation p.E66Q identified as the genetic etiology of Fabry disease using exome sequencing. , 2016, Gene.

[29]  R. Giugliani,et al.  Identification of mutations in Colombian patients affected with Fabry disease. , 2015, Gene.

[30]  Jing Zhou,et al.  Modelling kidney disease with CRISPR-mutant kidney organoids derived from human pluripotent epiblast spheroids , 2015, Nature Communications.

[31]  Benjamin S. Freedman.  Modeling Kidney Disease with iPS Cells , 2015, Biomarker insights.

[32]  K. Kolaja,et al.  Disease modeling and phenotypic drug screening for diabetic cardiomyopathy using human induced pluripotent stem cells. , 2014, Cell reports.

[33]  J. England,et al.  Fabry's disease , 2014, Journal of the Neurological Sciences.

[34]  F. Shibasaki,et al.  Plasma mutant α-galactosidase A protein and globotriaosylsphingosine level in Fabry disease , 2014, Molecular genetics and metabolism reports.

[35]  F. Weidemann,et al.  Female Fabry disease: significant improvement of Fabry disease-related gastrointestinal symptoms in a large cohort of female patients treated with agalsidase beta: data from the Fabry Registry , 2014 .

[36]  A. Kulkarni,et al.  A symptomatic Fabry disease mouse model generated by inducing globotriaosylceramide synthesis. , 2013, The Biochemical journal.

[37]  Mi Hee Lee,et al.  Possible role of transforming growth factor-β1 and vascular endothelial growth factor in Fabry disease nephropathy , 2012, International journal of molecular medicine.

[38]  T. Nishino,et al.  Identification of a Novel Mutation and Prevalence Study for Fabry Disease in Japanese Dialysis Patients , 2012, Renal failure.

[39]  B. Strulovici,et al.  Induced pluripotent stem cells — opportunities for disease modelling and drug discovery , 2011, Nature Reviews Drug Discovery.

[40]  N. Benvenisty,et al.  Epigenetic memory and preferential lineage-specific differentiation in induced pluripotent stem cells derived from human pancreatic islet beta cells. , 2011, Cell stem cell.

[41]  Yong Soon Chun,et al.  Applications of Patient-Specific Induced Pluripotent Stem Cells; Focused on Disease Modeling, Drug Screening and Therapeutic Potentials for Liver Disease , 2010, International journal of biological sciences.

[42]  P. Stenson,et al.  The Human Gene Mutation Database: 2008 update , 2009, Genome Medicine.

[43]  R. Brady,et al.  Elevated globotriaosylsphingosine is a hallmark of Fabry disease , 2008, Proceedings of the National Academy of Sciences.

[44]  R. Brady,et al.  Long-term correction of globotriaosylceramide storage in Fabry mice by recombinant adeno-associated virus-mediated gene transfer , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Benjamin S. Freedman,et al.  Differentiation of human kidney organoids from pluripotent stem cells. , 2019, Methods in cell biology.

[46]  B. Schermer,et al.  Enzyme Replacement Therapy Clears Gb3 Deposits from a Podocyte Cell Culture Model of Fabry Disease but Fails to Restore Altered Cellular Signaling. , 2019, Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology.

[47]  J. Blangero,et al.  Induced Pluripotent Stem Cells in Disease Modeling and Gene Identification. , 2018, Methods in molecular biology.

[48]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..